EGFR and non-small cell lung carcinoma: Brigatinib, a dual ALK and EGFR inhibitor, when combined with cetuximab (anti-EGFR antibody), showed promising efficacy against NSCLC with T790M/cis-C797S EGFR mutations in a preclinical study and a case report, respectively [112, 113].